Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]

Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]

Protox lands licensing deal in Japan

Protox Therapeutics (TSX:PRX) has signed a potential $75 million (U.S.) licence agreement with Kissei Pharmaceutical to develop and commercialize Protox’s PRX302 drug in Japan for the treatment of enlarged prostate, prostate cancer and other diseases of the prostate. Under the accord, Protox will receive an upfront payment of $3 million and is eligible to receive [...]

Analysts cut Labopharm price targets on marketing deal

After weighing the pros and cons of Labopharm’s joint venture marketing accord with Italy’s Gruppo Angelini, Dundee Securities and Versant Partners cut their price targets on “buy-rated” Labopharm (TSX: DDS; NASDAQ: DDSS), with Dundee moving the target down to $2.40 from $3 and Versant down to $2.50 from $3. Dundee analyst David Martin cited “increased [...]

Versant backs iCo interim efficacy data

iCo Therapeutics (TSX-V:ICO) reported interim efficacy data at a medical conference over the weekend from a few patients in its 15-patient Phase 1 diabetic macular edema trial testing its antisense drug iCo-007. Versant Partners analyst Doug Loe writes that the case-study data “showed solid evidence of iCo-007 impact on retinal thickness/macular edema at six months [...]

« Previous Page